Clinical Trial

A Study of QL1706 (an Anti-PD-1/CTLA-4 Combined Antibody) Combined With Albumin-bound Paclitaxel and Bevacizumab in the Treatment of Platinum-resistant Recurrent Ovarian Cancer

Unknown Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 19, 2024 (before its estimated February 2026 completion). Its status may not reflect the trial's current state.
Summary
* Major objectives To evaluate the efficacy of QL1706 combined with albumin-binding paclitaxel and bevacizumab in the treatment of platinum-resistant recurrent ovarian cancer. * Secondary Purpose To evaluate the safety of QL1706 in combination with albumin-binding paclitaxel and bevacizumab in the treatment of platinum-resistant recurrent ovarian cancer. Exploratory analysis of the association between the efficacy of the combination regimen and biomarkers.
Protocol Amendment History 1 change
critical Trial status changed: Not Yet Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT06509971
Lead Sponsor West China Second University Hospital
Conditions Platinum-resistant Recurrent Ovarian Cancer
Enrollment 39 participants
Start Date 2024-07
Primary Completion 2026-02 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2024-07-19